New Amsterdam Pharma 47th Annual Global Healthcare Conference Key Takeaways

NewAmsterdam Pharma (NAMS) provided updates on its PREVAIL cardiovascular outcomes trial at the 47th Annual Global Healthcare Conference. Key adjustments include re-powering for a 15% risk reduction and a broadened MACE definition, with a readout expected in early 2027.

Key Takeaways

• 1.NAMS suggests lower event rates in the PREVAIL trial are due to obicetrapib benefit.
• 2.4-point MACE definition now includes total revascularization, adding 20-24% more events.
• 3.Study re-powered to 15% relative risk reduction; interim analysis requires both 3-point and 4-point MACE to hit.

Table of Contents

• Valuation/Risks
• Disclosure Appendix
• GS Factor Profile
• M&A Rank
• Quantum
• Disclosures
• Company-specific regulatory disclosures
• Distribution of ratings/investment banking relationships
• Price target and rating history chart(s)
• Target price history table(s)
• Regulatory disclosures
• Ratings, coverage universe and related definitions
• Global product; distributing entities
• General disclosures

Document Preview

Page 1 of 1

Subscribe for full accessStart Free Trial